The regulatory landscape for biosimilars is shifting significantly in 2025. The FDA has taken two big steps that collectively make it faster and cheaper to bring many biosimilars to market: In June 2024, the FDA proposed to drop “switching” studies for the interchangeable designation, saying... Continue reading
Return to previous page